Restricted accessResearch articleFirst published online 2024-12
Peripheral mononuclear cells and systemic lupus erythematosus association: Integrated study of single-cell sequencing and mendelian randomization analysis
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease predominantly affecting women. Despite advances in treatment, recent developments in single-cell RNA sequencing (scRNA-seq) and Mendelian randomization (MR) continue to facilitate the need for precision medicine.
Methods
Data obtained from the GSE135779 dataset underwent quality control, normalization, and dimensionality reduction using Seurat and MonacoImmuneData. Marker genes identified subgroups for analysis with CellChat and ClusterProfilerR. MR analysis of these genes’ eQTLs was performed to establish causal relationships with SLE using IEU Open GWAS project data.
Results
Single-cell analysis revealed distinct cellular subtypes and highlighted increased monocyte levels in patients with SLE. MR analysis revealed 12 genes, particularly interferon induced protein with tetratricopeptide repeats 3 (IFIT3), causally related to SLE. Gene ontology and the Kyoto encyclopedia of genes and genomes analyses identified pathways significant to SLE pathogenesis. Visualization of these genes at the single-cell level revealed their role in disease progression. Cell communication differences between IFIT3-positive and -negative groups were also observed.
Conclusion
This study demonstrates the potential of scRNA-seq and MR in identifying critical factors in SLE pathogenesis, thereby supporting the need for targeted therapies. Identifying IFIT3, among other genes, as central to SLE progression opens new avenues for precision medicine approaches in SLE management.
LiuYTuZZhangX, et al.Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review. Front Cell Dev Biol2022; 10: 998328.
2.
MöckelTBastaFWeinmann-MenkeJ, et al.B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev2021; 20(2): 102736.
3.
WeinsteinAAlexanderRVZackDJ. A review of complement activation in SLE. Curr Rheumatol Rep2021; 23(3): 16.
4.
PanLLuMPWangJH, et al.Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr2020; 16(1): 19–30.
5.
LamriYCharlesN. IgE in the pathogenesis of SLE: from pathogenic role to therapeutic target. Antibodies2020; 9(4).
6.
BaechlerECBatliwallaFMKarypisG, et al.Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A2003; 100(5): 2610–2615.
7.
ChicheLJourde-ChicheNWhalenE, et al.Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol2014; 66(6): 1583–1595.
8.
LanderSAWallaceDJWeismanMH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus2002; 11(6): 340–347.
9.
SchneiderM. Target therapy in SLE. Autoimmun Rev2019; 18(1): 21–24.
10.
Guerrero-JuarezCFDedhiaPHJinS, et al.Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds. Nat Commun2019; 10(1): 650.
11.
HanXZhouZFeiL, et al.Construction of a human cell landscape at single-cell level. Nature2020; 581(7808): 303–309.
12.
Nehar-BelaidDHongSMarchesR, et al.Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat Immunol2020; 21(9): 1094–1106.
LarssonSCButterworthASBurgessS. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J2023; 44(47): 4913–4924.
15.
SekulaPDel Greco MFPattaroC, et al.Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol2016; 27(11): 3253–3265.
16.
BirneyE. Mendelian randomization. Cold Spring Harb Perspect Med2022; 12(4): a041302.
17.
BarrettTWilhiteSELedouxP, et al.NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res2013; 41(Database issue): D991–D995.
18.
SatijaRFarrellJAGennertD, et al.Spatial reconstruction of single-cell gene expression data. Nat Biotechnol2015; 33(5): 495–502.
19.
LallSSinhaDBandyopadhyayS, et al.Structure-aware principal component analysis for single-cell RNA-seq data. J Comput Biol2018; 3: 2.
20.
DoVHCanzarS. A generalization of t-SNE and UMAP to single-cell multimodal omics. Genome Biol2021; 22(1): 130.
21.
GeissmannFManzMGJungS, et al.Development of monocytes, macrophages, and dendritic cells. Science2010; 327(5966): 656–661.
22.
Ziegler-HeitbrockLHoferTP. Toward a refined definition of monocyte subsets. Front Immunol2013; 4: 23.
23.
WongKLTaiJJYWongWC, et al.Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood2011; 118(5): e16–e61.
24.
TanayASebé-PedrósA. Evolutionary cell type mapping with single-cell genomics. Trends Genet2021; 37(10): 919–932.
25.
McCrackenIRTaylorRSKokFO, et al.Transcriptional dynamics of pluripotent stem cell-derived endothelial cell differentiation revealed by single-cell RNA sequencing. Eur Heart J2020; 41(9): 1024–1036.
26.
YazarSAlquicira-HernandezJWingK, et al.Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science2022; 376(6589): eabf3041.
27.
BurgessSThompsonSGCRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol2011; 40(3): 755–764.
28.
BurgessSThompsonSG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol2017; 32(5): 377–389.
29.
FerenceBA. Interpreting the clinical implications of drug-target mendelian randomization studies. J Am Coll Cardiol2022; 80(7): 663–665.
30.
LiuGJinSJiangQ. Interleukin-6 receptor and inflammatory bowel disease: a mendelian randomization study. Gastroenterology2019; 156(3): 823–824.
31.
Perez-SanchezCBarbarrojaNMessineoS, et al.Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis2015; 74(7): 1441–1449.
32.
SasakiTBraceroSKeeganJ, et al.Longitudinal immune cell profiling in patients with early systemic lupus erythematosus. Arthritis Rheumatol2022; 74(11): 1808–1821.
33.
HiroseSLinQOhtsujiM, et al.Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int Immunol2019; 31(11): 687–696.
34.
RichterPMacoveiLAMihaiIR, et al.Cytokines in systemic lupus erythematosus-focus on TNF-α and IL-17. Int J Mol Sci2023; 24(19): 14413.
35.
GrebenciucovaEVanHaerentsS. Interleukin 6: at the interface of human health and disease. Front Immunol2023; 14: 1255533.
36.
Ferreté-BonastreAG. Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus. Ann Rheum Dis2024; 2: 1.
LinHSuiWTanQ, et al.Integrated analyses of a major histocompatibility complex, methylation and transcribed ultra-conserved regions in systemic lupus erythematosus. Int J Mol Med2016; 37(1): 139–148.
39.
JhaAJosephJPrabhuSB, et al.Utility of peripheral blood monocyte subsets, circulating immune complexes and serum cytokines in assessment of SLE activity: an observational, cross-sectional study. Clin Rheumatol2024; 43(1): 209–217.
40.
LópezPRodríguez-CarrioJMartínez-ZapicoA, et al.Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology2020; 59(7): 1795–17114.
41.
GiordanoDKuleyRDravesKE, et al.B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease. Front Immunol2023; 14: 1050528.
42.
DiekerJWvan der VlagJBerdenJH. Triggers for anti-chromatin autoantibody production in SLE. Lupus2002; 11(12): 856–864.
43.
CrowMK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis2023; 82(8): 999–1014.
44.
Ferreté-BonastreAGMartínez-GalloMMorante-PalaciosO, et al.Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus. Ann Rheum Dis2024; 83(7): 865–878.
45.
CrispinJCAlcocer-VarelaJ. The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmun Rev2007; 6(7): 450–456.
46.
WesterweelPELuijtenRKMACHoeferIE, et al.Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis2007; 66(7): 865–870.
47.
ShenMDuanCXieC, et al.Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. Front Immunol2022; 13: 962393.
48.
WangJDaiMCuiY, et al.Association of abnormal elevations in IFIT3 with overactive cyclic GMP-AMP synthase/stimulator of interferon genes signaling in human systemic lupus erythematosus monocytes. Arthritis Rheumatol2018; 70(12): 2036–2045.
49.
XiaoLZhanFLinS. Clinical values of the identified hub genes in systemic lupus erythematosus. Front Immunol2022; 13: 844025.
50.
HeZZhouSYangM, et al.Comprehensive analysis of epigenetic modifications and immune-cell infiltration in tissues from patients with systemic lupus erythematosus. Epigenomics2022; 14(2): 81–100.
51.
HuangXShenNBaoC, et al.Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells. Arthritis Res Ther2008; 10(4): R91.
52.
SiddiqiKZWilhelmTRUlff-MøllerCJ, et al.Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies. Transl Res2021; 238: 63–75.
53.
TengYLiSDingY, et al.Identification of significant genes and pathways for the chronic and subacute cutaneous lupus erythematosus via bioinformatics analysis. Dis Markers2022; 2022: 9891299.
54.
SkundricDSCruikshankWWDrulovicJ. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis. J Neuroinflammation2015; 12: 78.
55.
GlassWGSariskyRTVecchioAM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res2006; 26(8): 511–520.
56.
MulcahyHO'RourkeKPAdamsC, et al.LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection. Immunogenetics2006; 57(12): 893–903.
57.
Daßler-PlenkerJ. RIG-I activation induces the release of extracellular vesicles with antitumor activity. OncoImmunology2016; 5(10): e1219827.
58.
FurieRKhamashtaMMerrillJT, et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol2017; 69(2): 376–386.
59.
MaitraDBragazzi CunhaJElenbaasJS, et al.Porphyrin-induced protein oxidation and aggregation as a mechanism of porphyria-associated cell injury. Cell Mol Gastroenterol Hepatol2019; 8(4): 535–548.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
